Question about Docetaxel & Th1902I was wondering the following : Correct me if I missed something...
Docetaxel is often used at 75mg /m once every 3 weeks (month?)
The annual sales of Docetaxel in 2023 is around USD 115 billion and is projected to be USD 252 billion in 2032.
Theratechnologies have shown that there are no notable DLTs with the last cohort and not much before that as well for many patients. This, with about 3 times the dose (300mg/m).
Let's consider that they will succeed to show that their process with TH1902 each week for a total of 300mg/m has less or equal negative effect than Docetaxel alone at 75mg/m.
Wouldn't it be interesting for companies selling Docetaxel to add the peptide (well...using TH1902) to their treatments?
It seems that efficacy for ovarian cancer is less important than security with these patients that have shown very high resistance to many treatments before. Which is not the case when we use Docetaxel alone... or with other solutions to manage the negative effects.
Using 300mg/m on less resistant patients with less or same negative effect should show more efficacy, no?